524 related articles for article (PubMed ID: 24135405)
1. New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H; McCarthy P
Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
[TBL] [Abstract][Full Text] [Related]
2. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
3. Continuous treatment with new agents for newly diagnosed multiple myeloma.
Zou Y; Sheng Z; Lu H; Yu J
Anticancer Drugs; 2013 Jun; 24(5):527-33. PubMed ID: 23511426
[TBL] [Abstract][Full Text] [Related]
4. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
5. Role of consolidation therapy in transplant eligible multiple myeloma patients.
Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
[TBL] [Abstract][Full Text] [Related]
6. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
7. Initial treatment of transplant candidates with multiple myeloma.
Moreau P; Touzeau C
Semin Oncol; 2013 Oct; 40(5):585-91. PubMed ID: 24135403
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
McCarthy PL; Einsele H; Attal M; Giralt S
Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
[TBL] [Abstract][Full Text] [Related]
9. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy in multiple myeloma.
Harousseau JL
Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
13. Integrating novel therapies in the transplant paradigm.
Harousseau JL
Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
15. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
16. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Yaqub S; Ballester G; Ballester O
Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
[TBL] [Abstract][Full Text] [Related]
17. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang L; Ran X; Wang B; Sheng Z; Liu L
Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
[TBL] [Abstract][Full Text] [Related]
18. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
19. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of multiple myeloma.
Kyle RA
Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
